OBJECTIVE: Peripherally administered exendin-4 is in clinical trials for the treatment of diabetes mellitus and obesity. Since its effects on food intake are mediated centrally, we determined the degree and type of its blood-to-brain penetration of the mouse blood-brain barrier (BBB). MEASUREMENTS AND RESULTS: High-performance liquid chromatography showed that exendin-4 was stable in blood, with most of the injected peptide reaching the brain intact. Capillary depletion studies with washout showed that the injected exendin-4 reached brain parenchyma rather than being trapped in the endothelial cells composing the BBB. Multiple-time regression analysis showed that exendin-4 crossed the BBB directly at a fast rate. The rapid brain entry of exendin-4, helped by its high lipophilicity as demonstrated by the octanol/buffer partition coefficient, was not dependent upon circumventricular organs and was not affected by food deprivation for 24 h. The simultaneous i.v. injection of high doses of unlabeled exendin-4 resulted in self-inhibition (saturation) that only became statistically significant (Po0.05) when the results of four experiments were combined; this suggests a possible limit to the amount of peripherally administered exendin-4 that can reach the brain after injection of high doses. CONCLUSION: The results indicate that exendin-4 is well conformed for exerting central effects involved in the control of obesity.
Introduction
Exendin-4 is in clinical trials for the treatment of type II diabetes mellitus and associated obesity. Originally isolated from the saliva of the Gila monster, this 39 amino acid peptide has slightly more than 50% sequence homology with glucagon-like peptide (GLP)-1. GLP-1, however, is rapidly metabolized in blood, less than half remaining intact after 2 min. 1 Exendin-4 is much more potent in inducing satiety and weight loss in both lean and obese mice and rats, particularly after peripheral administration. 2, 3 The action of exendin-4 in reducing food intake is considered to be mediated centrally in the brain, 3 where its binding sites in places like the hypothalamus and thalamus are identical to those of GLP-1. 4 If the central effects of peripherally administered exendin-4 are direct, then it must cross the blood-brain barrier (BBB). Accordingly, we investigated whether exendin-4 crosses the BBB in intact form and whether this crossing is saturable.
Materials and methods

Animals
Adult male CD1 mice (Charles River, Wilmington, MA, USA), weighing about 22 g each, were anesthetized with urethane (4 g/kg, i.p.) and used as approved by the Institutional Animal Care and Use Committee.
Radiolabeling of the compounds
Exendin-4 (Heloderma Suspectum) was purchased from Phoenix Pharmaceuticals, Belmont, CA, USA. This 39 amino acid peptide has a molecular weight of 4184. Although it does not contain a Tyr, the N-terminal amino acid is His, permitting radiolabeling with 125 column. The gradient was 0-60% acetonitrile with 0.1% trifluoroacetic acid (B) for 40 min followed by 60-80% for 5 min and then 80% B for an additional 5 min. Peak fractions were pooled and aliquots were dried in a Speed Vac concentrator (Savant, Holbrook, NY, USA) and stored at À801C. To test whether these peptides were stable in vivo, they were injected into the jugular vein of anesthetized mice. Blood was collected from the carotid artery followed by immediate decapitation. Serum was tested by the same HPLC conditions as for purification. The brain was homogenized in the presence of a protease inhibitor cocktail (Sigma, St Louis, MO, USA) as well as 5.8 mM EDTA and 1.1 mM 1,10-phenanthroline to retard degradation induced by the homogenization procedure, and the supernatant was eluted with the same HPLC program. To compare the degradation occurring during tissue processing, the iodinated peptide was added to freshly harvested brain and blood of the anesthetized mouse, and brain supernatant and serum were processed and analyzed by HPLC.
Capillary depletion
To study the compartmental distribution of Tc-albumin in 200 ml of lactated Ringer's solution containing 1% albumin was injected into the jugular vein of anesthetized mice (n ¼ 4/group). Blood was collected from the descending abdominal aorta and the mouse was decapitated with or without intracardial perfusion to clear the cerebral vascular space. The cerebral cortex was harvested, weighed, and homogenized in capillary buffer with the addition of 26% dextran. The capillaries and brain parenchyma were separated by centrifugation of the mixture in a swinging bucket rotor at 41C, 5400 g, for 15 min, and radioactivity was measured in a dual-channel g-counter for both 125 Tc-albumin. For the study of the effect of food deprivation, food, but not water, was removed 24 h before the experiment. The control group had free access to food and water.
For study of the possible role of circumventricular organs (CVOs), cortex was separated from the rest of the brain and counted separately. The counts for cortex and those for the remainder of the brain were added for each mouse at each time to arrive at the cpm for the total brain. The K i for each of these three regions was determined as described above.
Perfusion with blood-free buffer In situ brain perfusion was performed in anesthetized mice in which the abdominal aorta was clamped and the bilateral jugular veins disrupted so as to generate an excorporeal system. The blood-free perfusate buffer was oxygenated for 10 min with 95% O 2 and 5% CO 2 . To this was added 125 Iexendin-4 at 0.6 Â 10 6 cpm/ml and 99m Tc-albumin at 1.6 Â 10 6 cpm/ml. The perfusion syringe was driven by a Harvard pump (model 975; Millis, MA, USA) at a rate of 2 ml/ min. Two groups of mice were studied (n ¼ 7/group, repeated three times for a total of 21/group). One group received radiolabeled compounds only; the other group received unlabeled exendin-4 at 2 mg/ml in addition to the radioactive compounds. The mice were decapitated at different time intervals between 1 and 5 min, and brain radioactivity was measured in a dual-channel g-counter for both 125 I-exendin-4 and 99m Tc-albumin. The ratios of radioactivity of brain over perfusate for each compound were plotted against perfusion time to derive the influx rate, which is the slope of the linear regression line.
Efflux after i.c.v. injection
Brain-to-blood studies were performed in mice (n ¼ 5/group) anesthetized with urethane. The scalp of the mouse was removed, and the right lateral ventricle was localized at 1 mm lateral and 0.2 mm posterior to the bregma and 2.5 mm deep. Octanol/buffer partition coefficient To a mixture of 125 I-exendin-4 and 1 ml of octanol was added 1 ml of a 0.25 M phosphate buffer solution at pH 7.4. After being vigorously mixed for 1 min and gently mixed for an additional 10 min, the two phases were separated by centrifugation at 4000 g for 10 min. Aliquots were counted for radioactivity and the partition coefficient was expressed as the ratio of cpm in the octanol phase to cpm in the buffer phase. The octanol/buffer partition coefficient measures lipophilicity.
Hydrogen bonding
The standard method for the determination of hydrogen bonding (desolvation potential) involves measurement of the difference between the logarithms of the partition coefficients in a hydrogen bonding solvent (octanol) and a nonhydrogen bonding lipophilic organic solvent (isooctane). 9,10 The procedure we used for the determination of the isooctane/buffer partition coefficient was identical to that described above for the octanol/buffer partition coefficient except that isooctane was substituted for the octanol.
Results
Stability of 125 I-exendin-4 in blood and brain
In serum, the percent intact 125 I-exendin-4, corrected for processing, was 100% at 10 min; at 30 min it was 97.7%. The corrected percent intact I-exendin-4 reached the brain parenchyma than was bound to the capillaries or was loosely adherent to the vasculature ( Figure  1 ). This shows that almost 90% of the exendin-4 injected i.v. reaches the brain parenchyma.
Entry of 125 I-exendin-4 into brain after i.v. injection
In each of four individual experiments (n ¼ 7/group) considered separately, excess (5 mg/mouse) unlabeled exendin-4 did not decrease the entry of 125 I-exendin-4 to a statistically significant extent. When the results of these four experiments were combined (n ¼ 28/group), however, the results became significant at a P-value of 0.048. For these combined experiments (Figure 2) , the K i of 125 I-exendin-4 was 4.621 7 0.557 Â 10 À4 ml/g min (r ¼ 0.85). Addition of 5 mg/ mouse unlabeled exendin-4 decreased the K i to 2.631 7 0.818 Â 10 À4 ml/g min (r ¼ 0.54). In a preliminary experiment, 1 mg exendin-4 was ineffective. This shows that exendin-4 readily enters the brain from blood, but that the entry rate may be limited when high doses are administered.
In each experiment, influx of 125 I-exendin-4 (with or without unlabeled exendin-4) was significantly (Po0.0001) faster than the K i of 99m Tc-albumin. The combined values for the 99m Tc-albumin were À1.688 7 1.118 Â 10 À4 ml/g min Tc-albumin were not significantly different from zero, indicating that an excess (5 mg) of the exendin-4 did not disrupt the BBB (Figure 2 ).
Exendin-4 shows the same affinity as GLP-1 to binding sites that are present in the CVOs. 4 Figure 3 shows the similar rates of entry of 125 I-exendin-4 into whole brain, cortex alone (devoid of CVOs and choroid plexuses), and the remainder of the brain (containing CVOs and choroid plexuses). This shows that most of the exendin-4 injected i.v. reaches the brain through the BBB rather than through CVOs. The entry of a few ingestive peptides with readily saturable transport systems into the brain is affected by food deprivation. 11, 12 Food deprivation for 24 h was without significant effect on the influx of 125 I-exendin-4.
Entry of 125 I-exendin-4 during in situ brain perfusion in blood-free buffer
In the blood-free in situ brain perfusion system, 125 I-exendin-4 was delivered at a constant rate together with 99m Tcalbumin. There was no significant inhibition in any of the three separate experiments, so the results were combined. As illustrated in Figure 4 , the combined group with only Brain-to-blood efflux of 125 I-exendin-4
There was a linear relationship between the logarithm of brain radioactivity and time for both 125 I-exendin-4
(r ¼ 0.94) and 99m Tc-albumin (r ¼ 0.91). The half-time disappearance was 14.6 min for 125 I-exendin-4 and 15.7 min for 99m Tc-albumin. The difference between the two regression lines was not statistically significant. These results are shown in Figure 5 . They fail to provide any evidence for a rapid transport system out of the brain for exendin-4 that might have confounded the determination of the rate of influx. 
Hydrogen bonding
The isooctane/buffer partition coefficient for 125 I-exendin-4 was 0.047 7 0.006. The difference between the logarithms of the octanol and isooctane partition coefficients, representing hydrogen bonding, was 0.344.
Discussion
Although there are several indirect ways by which a substance in blood can affect the brain, 13 we showed that exendin-4 is stable in blood and can directly penetrate the BBB in intact form. This was not dependent upon CVOs. Coadministration of albumin, used as the vascular control, showed that this did not occur by leakage. Entry, therefore, occurred either by transmembrane passive diffusion or by a saturable transport mechanism. For most ingestive peptides and polypeptides, one of these processes clearly predominates within the usual test range. For exendin-4, entry appeared to be passive except that a high dose of the peptide showed weak self-inhibition. This unusual situation is compatible with a transport system of limited capacity. It has practical implications for a compound with therapeutic potential since it might partially limit the effectiveness of very high doses. 20 and neuropeptide Y (NPY).
21
The octanol/buffer partition coefficient for exendin-4 was about the same as that for Phe 13 ,Tyr
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-melanin-concentrating hormone (MCH) 22 and less than that for the urocortins (UCN), 23 orexin A, 24 and cyloHis-Pro. 25 None of these peptides has a saturable transport system into the brain. Another physico-chemical determinant of penetration of the BBB is hydrogen bonding. It has been reported that hydrogen bonding potentialFthe energy required to desolvate polar amide bondsFrather than lipophilicity has the greatest influence on the passive diffusion of small Dphenylalanine containing model peptides in which the amide bond was sequentially N-methylated to alter the hydrogen bonding. 26 Using the same methods, we found that the hydrogen bonding value for 125 I-exendin-4 was less than half of that found for the three UCN peptides (the only ones measured by our group so far). Low hydrogen bonding potential might be advantageous for translocation to the highly apolar interior region of the cell membrane. The lipophilic and hydrogen bonding properties of exendin-4 are consistent with the ability of exendin-4 to readily cross the BBB. Its rate of entry is almost the same as that for insulin 27 and leptin. 6 Yet injection of only 1 mg/ mouse of excess insulin 28 or leptin 6,29 almost totally inhibited their entry into brain. For exendin-4, the larger dose of 5 mg/mouse only showed statistically significant inhibition of entry when the results of four experiments were combined, and even then the inhibition was much less than the inhibition seen for insulin and leptin with smaller doses. Together, our results show that intact exendin-4 readily enters the brain, but that there may be some limit to the extent of this entry at high doses.
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